Quick Answer
CRESCENT BIOPHARMA, INC. reported Total Assets of $240.29 million for the year ending 2025.
- CRESCENT BIOPHARMA, INC. showed an increase of +574.7% in Total Assets from 2024 to 2025.
- This data is from CRESCENT BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $58.06 million | Q2 2014: $67.52 million | Q3 2014: $62.43 million | Q1 2015: $48.46 million | Q2 2015: $62.04 million | Q3 2015: $55.74 million | Q1 2016: $40.70 million | Q2 2016: $55.77 million | Q3 2016: $48.01 million | Q1 2017: $37.17 million | Q2 2017: $121.62 million | Q3 2017: $115.82 million | Q1 2018: $247.42 million | Q2 2018: $235.70 million | Q3 2018: $225.17 million | Q1 2019: $204.44 million | Q2 2019: $192.33 million | Q3 2019: $180.45 million | Q1 2020: $162.10 million | Q2 2020: $158.35 million | Q3 2020: $150.42 million | Q1 2021: $138.02 million | Q2 2021: $124.38 million | Q3 2021: $107.94 million | Q1 2022: $81.46 million | Q2 2022: $65.04 million | Q3 2022: $55.96 million | Q1 2023: $68.92 million | Q2 2023: $61.82 million | Q3 2023: $53.20 million | Q1 2024: $34.20 million | Q2 2024: $24.42 million | Q3 2024: $15.70 million | Q1 2025: $5.99 million | Q2 2025: $157.43 million | Q3 2025: $138.27 million.
- Over the full 13 years of available data (2013 to 2025), CRESCENT BIOPHARMA, INC.'s Total Assets has grown by 4,448.0%.
- Historical annual values: Fiscal year 2025: $240.29 million | Fiscal year 2024: $35.62 million | Fiscal year 2023: $45.32 million | Fiscal year 2022: $51.81 million | Fiscal year 2021: $94.35 million | Fiscal year 2020: $142.83 million | Fiscal year 2019: $167.97 million | Fiscal year 2018: $214.84 million | Fiscal year 2017: $128.58 million | Fiscal year 2016: $42.39 million | Fiscal year 2015: $48.46 million | Fiscal year 2014: $57.26 million | Fiscal year 2013: $5.28 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: